ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Renal Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1474808
This article is part of the Research TopicEndocrine Regulation of Homeostasis of Water, Electrolytes and Organic SolutesView all 5 articles
Therapeutic effect and mechanism of gigantol on hyperuricemia
Provisionally accepted
tianshu Gao1
Jin Xu2
昱晗 贾1,3*
Youqiao Qian1
Naiqi Pei1
Wang Lilin1
Qiaohong Zheng1
Honglei Li4Zhen Chen1
Liu Yi Jiao1
Yang Ma1
Hui Chen1
Yuanyuan Ye1Jiaxin Zhao1
Yi Zhou1
陈 晓晴1
Baosheng Huang4Yefeng Liu2Yin Zhu2*Ning Xue2*Juan Zhang5*Guangfeng Ji5*
星 王1*- 1China Pharmaceutical University, Nanjing, Jiangsu Province, China
- 2Jiangsu University, Zhenjiang, Jiangsu Province, China
- 3Other, 中国南京, China
- 4Nanjing Medical University, Nanjing, Jiangsu Province, China
- 5Shandong Daizhuang Hospital, Jining, Shandong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study aimed to evaluate therapeutic effects of gigantol on hyperuricemia (HUA) and investigate the underlying mechanism hyperuricemia. Mouse model of HUA was made by gavage of potassium oxonate, and HK-2 and AML12 cell models were made by adenosine and xanthine oxidase induction. We tested the levels of uric acid (UA), CRE, BUN, cellular UA, and XOD activity. The levels of NLRP3 and other inflammatory factors were detected by ELISA kits. XOD, proteins related to the NLRP3 pathway, and UA transporters. We found that the levels of UA, CRE and BUN increased in serum but decreased in urine in HUA model mice. After gigantol treatment, UA, CRE and BUN levels in serum decreased, whereas their levels in urine increased. The levels of NLRP3 and IL-1β were lower and the expression of NLRP3 related protein decreased after gigantol treatment. In conclusion, gigantol exhibits therapeutic effect on HUA, and the mechanism may be related to inhibiting XOD activity to reduce UA production, regulating the expression of UA transporters to increase UA excretion, and inhibiting the activation of NLRP3 inflammatory signaling.
Keywords: Gigantol1, HUA2, xanthine oxidase inhibitor3, UA transporte4, NLRP35
Received: 02 Aug 2024; Accepted: 24 Jun 2025.
Copyright: © 2025 Gao, Xu, 贾, Qian, Pei, Lilin, Zheng, Li, Chen, Yi Jiao, Ma, Chen, Ye, Zhao, Zhou, 晓晴, Huang, Liu, Zhu, Xue, Zhang, Ji and 王. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
昱晗 贾, Other, 中国南京, China
Yin Zhu, Jiangsu University, Zhenjiang, 212013, Jiangsu Province, China
Ning Xue, Jiangsu University, Zhenjiang, 212013, Jiangsu Province, China
Juan Zhang, Shandong Daizhuang Hospital, Jining, Shandong Province, China
Guangfeng Ji, Shandong Daizhuang Hospital, Jining, Shandong Province, China
星 王, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.